Smith+Nephew SNN is strengthening its focus on surgical robotics through a new five-year partnership with Imperial College London. The collaboration is likely to establish a dedicated research center focused on technologies such as computer vision, sensing and markerless tracking to make robotic surgery less invasive, intuitive and accessible.
From an investor perspective, the partnership supports SNN’s long-term innovation strategy and could strengthen its competitive position in robotic surgery. Faster translation of academic research into commercial applications may expand the company’s technology pipeline and create opportunities for broader adoption of robotic solutions in musculoskeletal procedures. However, the financial benefits are likely to materialize over the longer term as the research progresses toward clinical and commercial applications.
Likely Trend of SNN Stock Following the News
Following the announcement, shares of SNN traded yesterday. Year to date, shares of the company have lost 9.5% compared with the industry’s 16.1% decline. However, the S&P 500 has risen 12.7% in the same timeframe.
The partnership could benefit SNN's long-term business by accelerating the development and commercialization of next-generation robotic surgery technologies. Access to Imperial College London’s expertise in computer vision, sensing and robotics may help SNN improve the precision, usability and scalability of its robotic platforms, potentially expanding adoption beyond specialist centers. Over time, a stronger robotics portfolio could support procedure growth, deepen surgeon engagement and enhance SNN’s competitive position in the growing orthopedic and musculoskeletal surgery market.
SNN currently has a market capitalization of $12.52 billion.
Image Source: Zacks Investment Research
More on the News
Smith+Nephew’s five-year collaboration with Imperial College London represents a new model for advancing medical technology from academic research to clinical application. The dedicated center is likely to bring together Imperial’s robotics researchers with SNN’s engineers and clinicians to co-develop technologies for robotic surgery in musculoskeletal procedures. The initiative will be led by Professor Ferdinando Rodriguez y Baena of Imperial’s Department of Mechanical Engineering and co-director of the Hamlyn Centre.
At full capacity, the center is expected to support a senior postdoctoral researcher and up to seven fully funded PhD studentships, with researchers being recruited progressively over the five-year program. The center is likely to be housed within Imperial’s Hamlyn Centre, part of the Institute of Global Health Innovation and a major research hub for robotic surgery.
Research will focus on technologies aimed at making robotic procedures less invasive and more accessible beyond specialist medical centers. One key area is markerless registration and tracking, which could eliminate the need for pins and rigid markers currently attached to bone, potentially reducing incisions and hardware requirements while improving consistency for surgeons.
The center is likely to explore computer vision technologies capable of interpreting and adapting to patient anatomy in real time. Unlike traditional approaches in which companies typically license university research or develop innovations independently, SNN plans to embed its experts directly within the academic environment. This approach is designed to shorten the path from research breakthroughs to operating-room adoption by combining Imperial’s engineering expertise with SNN’s clinical, technical and commercial capabilities. The initiative also marks SNN’s first university-based center of this kind and Imperial’s first industry center focused on medical technology.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global surgical robots market size is projected to increase from $17.2 billion in 2026 to $45.6 billion by 2033, at a CAGR of 14.9% from 2026 to 2033.
The industry is benefiting from the growing adoption of robotic-assisted minimally invasive procedures, rising demand for greater surgical precision and increased use of advanced robotic instruments and accessories across hospitals and surgical centers.
Other News
Smith+Nephew recently received FDA De Novo classification for its TESSA Spatial Surgery System, a cutting-edge accelerated computing and AI technology that combines personalized planning, augmented reality, advanced imaging, navigation and real-time tracking to enhance arthroscopic procedures. The technology originated with Perceive3D S.A., a University of Coimbra spin-off acquired by Smith+Nephew.
Smith+Nephew launched the LYNX COBLATION Laryngeal Wand, a multipurpose surgical device designed specifically for ENT surgeons performing airway procedures. The wand combines fine tissue dissection and rapid mass debulking in a single instrument to treat anatomies from the supraglottis to the trachea while operating at low temperatures.
SNN’s Zacks Rank & Key Picks
Currently, SNN has a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.